An aldohexose used as a source of energy and metabolic intermediate.
Chemical ID:
MESH:D005947
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [deuterohemin-alanyl-histidyl-threonyl-valyl-glutamyl-lysine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [diallyl trisulfide inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein]; 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; [3,4-Dihydroxyphenylacetic Acid co-treated with Glucose] results in increased phosphorylation of AKT1 protein; [Catechin co-treated with Glucose] results in increased phosphorylation of AKT1 protein; [Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein; Acetylcysteine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Acetylcysteine inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; deuterohemin-alanyl-histidyl-threonyl-valyl-glutamyl-lysine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; diallyl trisulfide inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [Glucose results in decreased expression of AKT1 protein modified form]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Rosiglitazone inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; [Glucose affects the susceptibility to INS protein] which affects the phosphorylation of AKT1 protein; ACACB protein affects the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Berberine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Fluorometholone inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Glucose inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]; Metformin inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]]; Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Rosiglitazone inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; spiraeoside inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Glucose co-treated with Calcitriol] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [SMARCA4A protein inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; [AKT1 protein mutant form results in increased susceptibility to Glucose deficiency] which results in increased phosphorylation of EIF4EBP1 protein; [Glucose co-treated with Calcitriol] results in increased phosphorylation of AKT1 protein; AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form results in increased susceptibility to Glucose deficiency]; AKT1 protein modified form inhibits the reaction [arsenite inhibits the reaction [INS1 protein results in increased uptake of Glucose]]; AKT1 protein modified form inhibits the reaction [monomethylarsonous acid inhibits the reaction [INS1 protein results in increased uptake of Glucose]]; AKT1 protein promotes the reaction [Glucose affects the phosphorylation of and affects the activity of FOXO3 protein]; Bezafibrate inhibits the reaction [AKT1 protein mutant form results in increased susceptibility to Glucose deficiency]; Glucose affects the phosphorylation of and affects the activity of AKT1 protein; methyl pyruvate inhibits the reaction [AKT1 protein mutant form results in increased susceptibility to Glucose deficiency]; PRKAA2 protein affects the reaction [AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form affects the susceptibility to Glucose deficiency]]; SMARCA4A protein inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]